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Abstract
Background Mantle cell lymphoma (MCL) is currently an
incurable entity, and new therapeutic approaches are needed.
We have applied a high-throughput phospho-proteomic tech-
nique to MCL cell lines to identify activated pathways and we
have then validated our data in both cell lines and tumor tissues.
Methods PhosphoScan analysis was performed on MCL
cell lines. Results were validated by flow cytometry and
western blotting. Functional validation was performed by
blocking the most active pathway in MCL cell lines.
Results PhosphoScan identified more than 300 tyrosine-
phosporylated proteins, among which many protein
kinases. The most abundant peptides belonged to proteins
connected with B-cell receptor (BCR) signaling. Active
BCR signaling was demonstrated by flow cytometry in
MCL cells and by western blotting in MCL tumor tissues.
Blocking BCR signaling by Syk inhibitor piceatannol
induced dose/time-dependent apoptosis in MCL cell lines,
as well as several modifications in the phosphorylation
status of BCR pathway members and a collapse of cyclin
D1 protein levels.
Conclusion Our data support a pro-survival role of BCR
signaling in MCL and suggest that this pathway might be a
candidate for therapy. Our findings also suggest that Syk
activation patterns might be different in MCL compared to
other lymphoma subtypes.
Keywords Mantle cell lymphoma . Proteomics .
PhosphoScan . Syk . Piceatannol . BCR signaling
1 Introduction
Mantle cell lymphoma constitutes about 6% of non-
Hodgkin lymphoma in the western world [1]. It shows a
characteristic clinical behavior with initial response to
therapy followed by relapses and death in 3–5 years.
Aggressive therapeutic regimens are promising, but to-date
MCL is still considered incurable, with the exception of a
small group of long-surviving patients. In recent years,
many high-throughput techniques have been applied to
MCL in order to gain insights into its pathogenesis, and to
discover suitable therapeutic targets [2–9]. These studies
have clarified a role for increased proliferation and
resistance to apoptosis in MCL, involving several signaling
pathways.
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A few studies from our group and also from others have
attempted the study of MCL from a proteomic point of view
[10–18]. Some of these studies were mainly focused on the
diagnostic implementation of proteomic techniques [14–16],
while other were more focused on the pathogenetic
mechanisms [12, 18–20]. These studies have identified
single up-regulated proteins in MCL compared to tonsil B-
cells [12], or several proteins up-regulated in MCL cell lines
compared to FL-derived cell lines followed by network
analysis [21]. More recently, a proteomic study focused on
the plasma membrane proteome of leukemic MCL and
compared it to normal B-cells [19]; this study identified
several alterations in the proteome of MCL lipid rafts that
might have therapeutic potential. In a previous study we
have focused our attention on the phospho-proteome of
several MCL cell lines by using immobilized metal affinity
chromatography (IMAC) pre-fractionation (a column-based
technique that selectively enriches all phospho-proteins by a
reversible binding to metal oxydes), followed by 2D-PAGE/
MS [20]. In that study we identified several activated
pathways that might reflect the biology of MCL, including
the alternative NF-kB pathway, the mTOR pathway and the
mitochondrial pathway. In the present work we have used a
complementary approach, called PhosphoScan, that involves
an immunoprecipitation of peptides by using an anti-
phosphotyrosine antibody followed by capillary electropho-
resis and MS identification of eluted peptides [22]. Com-
pared to IMAC, PhosphoScan should better dissect
phosphorylation profiles, specifically identifying tyrosine-
phosphorylated peptides. This approach has already been
successfully used in the phospho-profiling of primary [23]
and metastatic [24] lung cancer, in acute leukemia samples
[25], in Bcr/Abl positive cell lines [26], AML cell lines [27]
and Hodgkin lymphoma cell lines [28]. Since tyrosine
phosphorylation regulates the activity of many proteins, the
PhosphoScan approach can provide a picture of the most
active pathways in the analyzed samples. Moreover, since
many kinases are themselves activated by tyrosine phos-
phorylation, the profile of active kinases is also provided;
often these kinases are driving cell proliferation and survival,
and are therefore candidate targets for therapy.
In the current work, we used this approach to recognize
the most represented activated pathways in MCL cell lines.
We then verified the presence of these activated molecules
in MCL cell lines and tumor tissues. We subsequently
explored the functional role of the most activated pathway
in MCL cell lines by inhibition experiments.
2 Results and discussion
In the current paper we describe the results obtained from the
application of PhosphoScan to MCL cells. This is to our
knowledge the first use of this technique in MCL; we report a
large amount of data with precise identification of phosphor-
ylation sites for each protein, some of which novel.
2.1 PhosphoScan analysis identifies the tyrosine-activated
phosphoproteome of MCL cell lines and identifies B-cell
receptor signaling as the most active pathway
PhosphoScan analysis identified 421 unique tyrosine-
phosphorylated peptides, corresponding to 341 proteins,
ranked by overall abundance in Table 1 (for a complete list
of peptides and complete MS information see Supplemental
Table 1). Interestingly, several identified proteins mapped
to cytogenetic loci that have been reported to be altered in
MCL [29–31]. Among these, several activated protein
kinases were identified (Fig. 1), that are therefore appealing
as potential therapeutic targets.
The three most represented phospho-peptides are cyclin-
dependent kinases Cdc2, CDK2 and CDK3. Cdc2 (CDK1)
is actually part of the proliferation signature able to predict
prognosis in MCL [8] and has also been validated at the
immunohistochemical level [32]. CDK2 gains have been
detected in MCL in a variable proportion of cases [30, 31,
33], and have been associated with a poor prognosis [33].
CDK3 is less studied compared to other cyclin-dependent
kinases, but its locus has also been reported as subject to
gains [31, 34]. Its involvement in MCL is a novel finding,
although the role of CDK3 as an oncogene has been
demonstrated in other models [35, 36].
Syk and many other BCR pathway members were then
found. Many kinases belonging to this pathway (e.g. Syk, Lyn,
Hck, Btk, PKC-delta), were among the most represented
phospho-peptides identified by the PhosphoScan approach,
and this was confirmed when looking for non-random
enrichment of Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways [37] compared to the hypothesis of random
distribution. This analysis showed that (using a cutoff value of
more than five total peptides), the most enriched pathway was
hsa04662:B cell receptor signaling pathway (17.16-fold
enrichment) (for complete data see Supplemental Table 2).
Many of the proteins belonging to the most enriched
pathways were either present in different pathways (redun-
dant) or are functionally connected. Manual annotation by
literature search revealed that several of these, in the
topmost part of the ranking, were connected to BCR
signaling, even if not present in the canonical KEGG
BCR pathway (Table 1 and Fig. 2).
2.2 The presence of active B-cell receptor signaling
is validated in MCL cell lines and tissues
To further verify the functional role of BCR signaling in
MCL, we analyzed the phosphorylation status of Syk, Lyn,
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Table 1 Top 50 phospho-peptides identified (number of phospho peptides corresponding to the specific protein is reported. For complete list and
exact phosphorylation sites, see suppl. Table 1)
Protein name Granta-519 Jeko-1 MAVER-1 Rec-1 BCR pathway Kynase
Cdc2 17 38 16 26 *
CDK2 10 34 14 18 *
CDK3 10 33 13 17 *
Syk 9 19 24 3 * *
SHIP 7 18 10 10 *
PAG 9 14 4 8 *
PRP4 3 19 8 2 *
Lyn 4 10 9 7 * *
Ig-beta 0 22 2 0 *
Hck 3 8 5 3 * *
WASP 2 7 4 3 *
SHP-1 4 7 4 1 *
Btk 0 11 4 1 * *
cofilin 1 2 7 5 1
SgK223 6 1 4 4 *
LANP-L 0 6 5 3
PKCD 4 3 2 4 * *
GCET2 5 7 1 0 *
HSP90B 5 5 0 2
GSK3A 2 3 4 3 * *
GSK3B 2 3 4 3 * *
p38-alpha 2 3 6 1 * *
hnRNP A1 5 2 3 1
GRF-1 1 4 2 4
SPTBN1 0 5 4 1
SPTBN1 iso2 0 5 4 1
PLCG2 2 4 3 0 *
DYRK1A 1 4 3 1 *
Lck 4 2 1 2 * *
HSP90A 2 4 1 1
Blk 2 3 2 1 * *
IRAP 1 4 3 0
DDX3 4 3 0 0
PL10 4 3 0 0
Cbl-b 1 3 1 1 *
BCAP 1 4 1 0
Dok3 0 6 0 0 *
ANXA2 1 2 2 1
VIM 2 2 2 0
L-plastin 0 4 2 0
ENO1 0 2 2 2
PIK3R1 1 2 2 1 * *
DYRK1B 1 2 2 1 *
Src 1 2 1 2 * *
Fyn 1 2 1 2 * *
Yes 1 2 1 2 *
hnRNP 2H9 2 3 1 0
hnRNP U 2 3 1 0
hnRNP U iso2 2 3 1 0
PAI-RBP1 2 2 2 0
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Btk, Blnk and GSK3alfa/beta in MCL cell lines. Although
not present in the top 50 phospho-peptides, Blnk was
investigated because it is considered a classical downstream
molecule of the BCR pathway. The presence of basal levels
of phospho-Syk Y525 and Y323, as well as of phospho-
Blnk (Y84) was verified by flow cytometry (Fig. 3). By this
technique, we could detect no basal levels of phospho-Syk
Y352. In addition basal levels of phospho-Lyn (Y396 and
Y507) and also of downstream effectors phospho-Btk
(S180) and phospho-GSK3alfa/beta (S9/21) were demon-
strated by flow cytometry (Supplemental Figure 1). BCR
pathway activation in cell lines is somehow intriguing since
it is present in absence of an appropriate antigen stimula-
tion, and is therefore probably self-sustained by tumor cells,
either by side-by-side activation or by auto-activation.
In order to verify whether we could find this activation
in MCL tumors as well, we resorted to western blotting
analysis of phosphorylated forms of BCR pathway mem-
bers. This analysis showed that the activated forms of Syk
(in 5/6 cases, 83%), Lyn (in 6/6 cases, 100%), and Blnk (in
6/6 cases, 100%) were present also in MCL tumor tissues
(Fig. 4), therefore supporting the in vivo role of active BCR
signaling; as far as we know, this is the first report of the
presence of active (phosphorylated) BCR pathway mem-
bers in MCL tissues.
The activation of the BCR pathway in MCL has been
hypothesized in a previous paper based on cytogenetic and
RNA studies [6], but to our knowledge this is the first
protein-based and data-driven study that supports this
hypothesis. Another proteomic study focusing only on the
plasma membrane [19] showed an abnormal association of
PKCbeta to the cell membrane in MCL leukemic cells,
indirectly supporting an active BCR signaling.
Recent studies have shown the importance of tonic BCR
signaling in DLBCL [38, 39] and B-CLL [40], with a basal
activation of phospho-Syk residue Y352, while Y525 was
detected only after BCR cross-linking. The presence of
significant basal levels of phospho-Syk Y525 and Y323,
with no detectable phospho-Syk Y352 in basal conditions
in MCL cells are not concordant with what has been
reported in B-CLL and DLBCL [40], and suggest a
different pattern of activation of BCR signaling in MCL.
A recent report of a phase 1/2 clinical trial of
fostamatinib disodium, the first clinically available oral
Syk inhibitor, in patients with recurrent B-cell non-
Hodgkin lymphoma, showed that only 1 in 9 MCL
showed some response [41]. Several explanations might
be possible for this low response rate. First, the specificity
of this drug for Syk has been recently questioned [39].
Second, relapsed lymphomas might have evolved into
BCR-independent clones (such as the cell line Rec-1).
Third, since our data support the hypothesis that the
activation pattern of Syk in MCL is different from B-CLL
and DLBCL, it is possible that this phenomenon influen-
ces the response to fostamatinib.
2.3 Inhibition of Syk induces apoptosis in MCL cell lines
Since the proteins belonging to the BCR signaling pathway
were shown to be active, we tested the effect of the
blockade of this pathway on MCL cells. For this purpose,
Syk activity was inhibited by a widely used inhibitor,
piceatannol [42–45], a natural stilbene also resulting from
the hepatic metabolism of resveratrol, a compound found to
Fig. 1 List of protein kinases identified by the PhosphoScan
approach, ranked by overall abundance in the four MCL cell lines
analyzed. Color intensity proportional to the number of peptides (see
figure for color corresponding to the average number of peptides per
cell line)
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be pro-apoptotic for the MCL cell line Jeko-1 [11]. The
Rec-1 cell line showed a marked hypersensitivity to
DMSO, and it was deemed unfit for further experimental
work, which was conducted on less sensitive cell lines.
Piceatannol induced apoptosis in MCL cell lines Jeko-1,
UPN-1, Mino, Maver-1 and Granta-519, as evidenced by
Annexin V staining, with a LD50 varying from 9.50 μM to
28.91 μM at 24 h and 5.51 μM and 23.54 μM at 48 h
(Supplemental Table 3 and Fig. 5).
Interestingly, Jeko-1, which is very sensitive to picea-
tannol, also shows the highest number of phospho-peptides
belonging to the BCR pathway (Supplemental Table 4).
Apoptosis was dose and time dependent being visible
after 4 h of treatment in Jeko-1, but only after 16 h in
MAVER-1 (data not shown).
2.4 Inhibition of Syk down-regulates Cyclin D1 protein
levels
Cyclin D1 protein levels were massively down-regulated in
treated cells, as densitometric analysis showed a drop by 85
to 90% compared to untreated cells (Supplemental
Figure 2). The corresponding CCND1 mRNA was down-
regulated after piceatannol treatment, showing 22% to 71%
decrease (after normalization) in five tested cell lines
(Supplemental Figure 3). This decrease was however
significant only in three cell lines, namely UPN-1 (54%
decrease; p=0.047), Granta-519 (71% decrease; p=0.0078)
and MAVER-1 (69% decrease; p=0.008).
This finding is interesting, considering that the CCND1
gene is translocated under the control of a strong enhancer
such as the Igμ enhancer. A hypothetical scenario could be
hypothesized in which BCR signaling and CCND1 gene
transcription are connected, possibly via Syk. Cyclin D1
has been shown to be a Syk target gene in breast cancer and
other cells [46]. It is possible that CCND1 gene transcrip-
tion is directly repressed by Syk, in accordance to the fact
that normal B cells show very low levels of this protein and
at the same time nuclear localization of Syk. As previously
stated, in support of this hypothesis Syk acts as a
transcriptional repressor of the CCND1 gene in breast
carcinoma cells, and this activity is necessary for its tumor-
suppressor function [46]. One hypothesis is that in MCL
cells Syk might act via Stat3, a known CCND1 gene
transcription inducer, as suggested by a recent publication
[47]. In support of this hypothesis, the phosphorylation
of Stat3 was reduced by piceatannol in MCL cell lines
(Supplemental Figure 4), while total Stat3 was reduced in
Jeko-1 and UPN-1, but not significantly in Maver-1 and
Granta-519. According to these data, while the phosphor-
ylation of Stat3 was reduced in all cell lines, the total
level is reduced only in sensitive ones. Several publica-
tions support a role for Stat3 in the pathogenesis of MCL
[48–52].
According to our data the down-regulation of CCND1
mRNA cannot explain the whole picture, since it was
significant only in three cell lines after normalization using
an unrelated transcript. An increase in Cyclin D1 degrada-
Table 2 Antibodies used in the study
Primary antibody Clone Source Dilution Use
Bax Polyclonal Cell Signaling 1:1000 Western blotting
Bcl-xL 54H6 Cell Signaling 1:1000 Western blotting
Bcl-2 124 DakoCytomation 1:4000 Western blotting
Caspase 9 Polyclonal Cell Signaling 1:1000 Western blotting
Cyclin D1 SP4 LabVision 1:1000 Western blotting
p21 SX118 DakoCytomation 1:200 Western blotting
p27 SX53G8 DakoCytomation 1:200 Western blotting
p53 DO-7 Novocastra 1:500 Western blotting
Syk Polyclonal Cell Signaling 1:1000 Western blotting
P-Syk (Y525/526) C87C1 Cell Signaling 1:200 Western blotting
Stat3 124H6 Cell Signaling 1:4000 Western blotting
P-Stat3(Y705) D3A7 Cell Signaling 1:500 Western blotting
PE-P-Syk (Y352) 17A/P-ZAP70 BD Biosciences 1:100 Flow cytometry
P-Syk (Y525/526) Polyclonal Cell Signaling 1:100 Flow cytometry/immunofluorescence
P-Syk (Y323) EP573Y Abcam 1:100 Flow cytometry
P-BLNK (Y84) J117-1278 BD Biosciences 1:100/1:1000 Flow cytometry/western blotting
P-Btk (S180) 3D3 Cell Signaling 1:100 Flow cytometry
P-Lyn (Y507) Polyclonal Cell Signaling 1:100 Flow cytometry
P-Lyn (Y396) EP503Y Abcam 1:100/1:200 Flow cytometry/western blotting
P-GSK3α/β (S9/21) 37F11 Cell Signaling 1:100 Flow cytometry
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tion is another possible explanation, and might operate
alongside transcription repression. In support of this
complementary hypothesis is the reduction of GSK3
phosphorylation on negative regulatory serine residues,
which increases its kinase activity with subsequent phos-
phorylation and degradation of Cyclin D1 [53].
SYK mRNA was significantly down-regulated by picea-
tannol treatment in UPN-1 and MAVER-1 (59% and 75%
reduction; p=0.047 and p=0.01 respectively). It was also
reduced in Granta-519, but the values did not reach
statistical significance (49% reduction; p=0.11). SYK
mRNA was increased after treatment in Jeko-1 and Mino
(by 7% and 40% respectively) although values were not
statistically significant (p=0.8 and p=0.32 respectively).
Modifications of mRNA levels of SYK and CCND1 showed
a good correlation with an r=0.88 (Supplemental Figure 3).
2.5 Piceatannol-induced apoptosis involves the activation
of the intrinsic pathway, and is accompanied
by the modification of several regulators of cell cycle
and apoptosis
Apoptosis was triggered trough the intrinsic pathway,
involving Caspase 9 cleavage, as shown by western blotting
experiments. Cleaved Caspase 8 levels were actually lower in
the treated samples than in the untreated ones (not shown).
Several apoptosis (Bcl-2, Bcl-xL, Bax, p53, p21), cell-cycle
related (p53, p21, p27) molecules were investigated by
western blotting. All investigated proteins showed the same
behavior in all cell lines with the exception of Bax
(Supplemental Figure 5). In detail, p53 levels were increased
after treatment (Jeko-1 resulted completely p53-negative due
to the presence of a truncating mutation, while other cell
lines with the exception of Granta-519 bear a missense
mutation [54]); p21 was strongly down-regulated; p27 was
cleaved with a decrease of the 27 kDa isoform and increase
of the 23KDa isoform; Bcl-2 was slightly increased, Bcl-xL
was decreased, while Bax was increased in Jeko-1 and
decreased in other cell lines. The mechanism inducing the
increase of Bax (a pro-apoptotic Bcl-2 family member) in
Jeko-1 is not clear, but this phenomenon might indicate a
more pronounced perturbation of mitochondrial outer mem-
brane potential [55]. The only clear-cut genomic abnormality
that might suggest a stronger Syk-dependance of Jeko-1 is
the presence of the amplification of the SYK locus [6],
although this cell line also bears a peculiar missense
mutation of TP53 (in addition to a deletion of the other
allele) that causes a premature stop codon with degradation
of its mRNA [5], and at variance with other cell lines shows
no p53 at all; this condition might cause an abnormal
regulation of BAX, that is a known p53 target gene [56].
2.6 Piceatannol induces complex modifications of the Syk
phosphorylation pattern and alterations of downstream
effectors of the B-cell receptor pathway
To verify the effects of piceatannol on the pattern of
phosphorylation of Syk and other BCR pathway members,
we resorted to flow cytometry using phospho-specific
antibodies. These experiments showed that piceatannol
induced a marked decrease in phospho-Syk tyrosine
residues Y525 and Y323, while unexpectedly the levels of
Y352, which were almost negative in basal conditions,
increased after treatment (Fig. 6). This residue resides in the
linker region of Syk, in a stretch that is essential for nuclear
localization, since a mutant lacking residues 332–359 was
unable to enter the nucleus, as reported by a previous article
[57]. These modifications were detectable after 6 h of
treatment, but not after two (data not shown). As previously
stated, B-CLL and DLBCL cells show a basal activation of
Fig. 2 Simplified diagram showing some of the identified BCR
pathway members. In red, activating members; in green, inhibiting
members; for some members the precise final effect is not clear; in
grey, other proteins known to be present but not identified. Full
arrows: direct interaction/activation; dotted arrows: indirect interac-
tion/activation. Data derived from Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway [37] and from published literature. KEGG
is a widely used annotated database of pathways, ligands and genes
(http://www.genome.jp/kegg/)
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Syk Y352, but no information is available for comparison
about how this phosphorylation might be changed by Syk
inhibition.
The levels of the downstream effectors phospho-Blnk
and phospho-Btk were also reduced by piceatannol treat-
ment in Jeko-1 and to a lesser degree in MAVER-1 cells
(Supplemental Figure 6).
To obtain independent information about the modifica-
tions of phospho-Syk after treatment, we used immunoflu-
orescence microscopy. These experiments showed that in
basal conditions phospho-Syk (Y525) is present in all cell
lines tested, and is apparently confined to the cytoplasmic
compartment of MCL cell lines (with the exception of
Granta-519, that showed also a partial nuclear localization).
After piceatannol treatment phospho-Syk (Y525) was
down-regulated in the cytoplasm, but its presence could
be demonstrated in the nucleus of MCL cell lines (Jeko-1,
UPN-1, Mino, Granta-519, MAVER-1) (Fig. 7). This
finding is in accordance with the reduction of phospho-
Syk (Y525) detected by antibodies used in flow cytometry
Fig. 4 Western blotting analysis
of MCL tissues. The presence of
phospho-Syk (Y525), phospho-
Lyn (Y396) and phospho-Blnk
(Y84) is shown in six MCL
tumor tissues. Cases 1, 2, 5 and
6 were classical MCL, while
cases 3 and 4 were blastoid
variants
Fig. 3 Analysis of basal levels
of phosphorylated Syk and Blnk
residues by flow cytometry. In
grey, isotypic control; in red,
basal levels. On the X axis,
arbitrary fluorescence units (log
scale); on the Y axis, cell count
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experiments, which were able to enter the cytoplasm but
not the nucleus in our experimental conditions.
One possible hypothesis to explain this phenomenon is
the fact that Syk has two known splice variants, of which
only the longest is able to enter the nucleus [58]. Western
blotting experiments in the five MCL cell lines Jeko-1,
Granta-519, MAVER-1, UPN-1 and Rec-1 showed that
only one band was identifiable in the expected molecular
weight range. A proteolytic 36 kDa isoform of Syk was
also detected (data not shown), although the significance of
this isoform described in erythrocytes [59], is still not clear
in our cells, because it might be either a true functional
variant or an experimental artifact. The absence of the
shortest splice variant of Syk was also demonstrated by
isoform-specific SYK RT-PCR experiments (Supplemental
Figure 7). This was confirmed using two amplicons of
different length as previously described [58]. The nuclear
exclusion phenomenon therefore is probably not related to
Syk differential splicing, but more probably to functional
modifications of the protein, such as phosphorylation.
3 Conclusions
Our study has identified a large number of phosphorylated
proteins and several activated pathways in MCL cells,
Fig. 5 Induction of apoptosis in
MCL cell lines. Upper panel
shows the percentage of live
cells (Y axis) in function of the
piceatannol concentration (X
axis) at 24 h. Lower panel
shows the same variables at 48 h
of treatment. Annexin V stain-
ing was used to discriminate
apoptotic cells
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which deserve a more thorough investigation by functional
validation experiments. Our experimental data suggest that
active BCR signaling is present in MCL cell lines and
tumors, and that it plays a role in the survival of MCL cells;
Syk is possibly one of the key molecules in this event, and
it might have a double-face role in the cytoplasmic and
nuclear compartments.
Our data also suggest that piceatannol, resveratrol or
their analogues could represent a therapeutic option for
patients with MCL if in vitro data will be confirmed in
vivo.
4 Methods
Cell lines MCL cell lines Jeko-1, Granta-519 and Rec-1
were purchased from DSMZ (Braunschweig, Germany).
Cell line MAVER-1 was developed in our laboratory [60].
Cell line Mino was obtained from ATCC (Manassas, VA,
USA). UPN-1 cells were kindly provided by Dr. Elias
Campo (Barcelona, Spain). Due to over-sensitivity to
DMSO-induced apoptosis, Rec-1 cells were not used for
apoptosis-induction assays.
Tumor samples Tumor samples were collected from the
archives of the Department of Pathology and Diagnos-
tics of the University of Verona. Informed consent had
been collected for all patients and procedures were
carried out according to the ethical guidelines of the
University Hospital of Verona with the approval of an
ethics committee, in compliance with the Helsinky
Declaration.
PhosphoScan analysis PhosphoScan analysis was per-
formed as previously described [23] on MCL cell lines
MAVER-1, Granta-519, Jeko-1, and Rec-1.
The phospho-proteins identified using this analysis were
categorized into KEGG Pathways using the DAVID Ease
web framework [61]. For P-value and fold enrichment
calculation the complete list of human genes was consid-
ered as a background. The calculation was repeated for lists
obtained by selecting genes above the abundance cut-offs
of 3, 4 and 5.
Illustrations were produced using the R statistical
software package (http://www.r-project.org).
Flow cytometry Flow cytometric analysis of several
tyrosine-phosphorylated forms of Syk (Y323, Y352 and
Y525) and downstream target phospho-BLNK was per-
formed as previously described [38] using antibodies
shown in Table 2. All experiments were performed in
triplicate.
RNA isolation and cDNA synthesis RNA isolation was
performed using the Allprep DNA/RNA/Protein Mini Kit
(Qiagen GmbH, Hilden, Germany), and RNA quality was
assessed by using an Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA, USA) and RNA 6000 Nano
chips (Agilent Technologies). Each cDNA was synthesized
from 1 μg total RNA using random primers and the Superscript
III First-strand synthesis system (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions.
RT-PCR The analysis of SYK isoforms was performed as
previously described [58]. Reaction products were ana-
Fig. 6 Modification of Syk
phosphorylation profile follow-
ing piceatannol treatment. After
treatment, phosphorylation of
residues Y525 and Y323 is
reduced, while that of residue
Y352 is increased. Red, untreat-
ed cells; blue, treated cells; solid
grey, isotypic control
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lyzed by the Agilent 2100 Bioanalyzer and the DNA1000
Chip (Agilent Technologies).
Quantitative RT-PCR Quantitative RT-PCR mRNA expres-
sion analysis was performed on ABI PRISM 7900HT Fast
Real-time PCR System (Applied Biosystems, Foster City,
CA) using Power SYBR green PCR Master Mix (Applied
Biosystems). Oligonucleotide primers used were: CCND1-
F AACTACCTGGACCGCTTCCT, and CCND1-R
GGGGATGGTCTCCTTCATCT; TBP-F, GCACAG
GAGCCAAGAGTGAA, and TBP-R, TCACAGCTCCC
CACCATATT.
TATA box binding protein (RefSeq ID NM_003194.3)
transcript level was used to normalize SYK expression.
Calibration curves for each couple of primers were
obtained by serial dilution of cDNA. Expression data were
analyzed by the comparative threshold cycle (Ct) method
accordingly to User Bulletin No. 2 (Applied Biosystems).
All experiments were performed in triplicate. The statistical
significance of the data was investigated by Student’s t-test.
All P values were two sided and considered significant
when less than 0.05.
Syk inhibition experiments Piceatannol (Sigma-Aldrich
Chemie GmBH, Steinheim, Germany) was resuspendend in
DMSO as a 100 mM stock. Cells were diluted at 500*103/ml
in RPMI 1640 (1% fetal calf serum) and let grow for 16 h.
Piceatannol was then added at concentrations between 1 μM
and 80 μM (depending on the sensitivity of cell lines). Cells
were harvested at 24 and 48 h and apoptosis levels analyzed
by Annexin V (Annexin V–FITC apoptosis detection kit I,
BD) as previously described [11]. All experiments were
performed in triplicate.
Western blotting Immunoblotting was performed by stan-
dard methodology, using the antibodies and dilutions
indicated Table 2. Protein content of samples was measured
using a colorimetric method (DC protein assay, Bio-Rad).
All lanes were loaded with the same amount of total protein
(in duplicate or triplicate), and were also visually verified
by Ponceau red staining after electroblotting.
Immunofluorescence Immunofluorescence was performed
using the antibodies shown in Table 2 (both primary and
secondary antibodies were diluted 1:100). Briefly, cells
were washed in PBS, deposited on charged slides by
gravity, fixed in cold methanol (−20°C) for 20 min and then
air-dried. Cells were then re-hydrated, incubated with
protein blocking solution for 10′, then incubated serially
with primary and secondary antibodies (with three washes
in PBS in-between). Slides were examined under fluores-
cent light using an Olympus BX61 microscope. Images
were acquired using appropriate filters via a monochromat-
ic camera cooled CCD camera (iAi, Japan) and analyzed
using the Olympus Cytovision software.
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Fig. 7 Localization of phospho-Syk following piceatannol treatment.
P-Syk Y525 (shown in green pseudo-color) disappears from the
cytoplasm and appears in the nucleus after treatment in all cell lines.
Nuclei counter stained in blue pseudo-color (DAPI staining)
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